MedPath

Radium-223 Dichloride Long-term Follow-up Program

Phase 3
Completed
Conditions
eoplasm Metastasis / Bone and Bones
Registration Number
JPRN-jRCT2080224668
Lead Sponsor
Bayer Yakuhin, Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
completed
Sex
Male
Target Recruitment
0
Inclusion Criteria

Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial

Exclusion Criteria

Not applicable to this follow up study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath